Cargando…

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

SIMPLE SUMMARY: B-cell malignancies, like leukemias and lymphomas, are neoplasms that emerge from the malignant proliferation of B cells. Hematopoietic stem cell transplant (HSCT) is an effective medical treatment for these malignancies, but unfortunately, relapse of the disease after HSCT remains a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartoló-Ibars, Ariadna, Uribe-Herranz, Mireia, Muñoz-Sánchez, Guillermo, Arnaldos-Pérez, Cristina, Ortiz-Maldonado, Valentín, Urbano-Ispizua, Álvaro, Pascal, Mariona, Juan, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470158/ https://www.ncbi.nlm.nih.gov/pubmed/34572890 http://dx.doi.org/10.3390/cancers13184664

Ejemplares similares

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
por: Ramírez-Chacón, Alejandro, et al.
Publicado: (2022)

Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments
por: Ramírez-Chacón, Alejandro, et al.
Publicado: (2022)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients
por: Perez-Amill, Lorena, et al.
Publicado: (2018)

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
por: González-Brito, Adrián, et al.
Publicado: (2023)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023)

Manufacturing and Management of CAR T-Cell Therapy in “COVID-19’s Time”: Central Versus Point of Care Proposals
por: Ortiz de Landazuri, Iñaki, et al.
Publicado: (2020)

Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
por: Cerrano, Marco, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
por: Fonseca-Hial, Ana Marcela Rojas, et al.
Publicado: (2016)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant
por: Malhotra, Bharat, et al.
Publicado: (2015)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Clinical Allogeneic and Autologous Islet Cell Transplantation: Update
por: Matsumoto, Shinichi
Publicado: (2011)

Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation
por: Nayak, Deepak Kumar, et al.
Publicado: (2016)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas
por: Reimer, Peter
Publicado: (2010)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea
por: Park, Sun Hee, et al.
Publicado: (2006)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023)

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells
por: Orio, Francesco, et al.
Publicado: (2014)

SHIPi Enhances Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Fernandes, Sandra, et al.
Publicado: (2015)

Editorial: Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy
por: Sharma, Nidhi, et al.
Publicado: (2023)

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder Really Two Distinct Diseases?
por: Zambello, Renato, et al.
Publicado: (2014)

Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
por: Moreno-Castaño, Ana Belen, et al.
Publicado: (2023)

Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment
por: Hassan, Mohd Nazri, et al.
Publicado: (2019)

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
por: Valton, Julien, et al.
Publicado: (2015)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fd8lt0ki452q3ctr6fnkpigc9o